Table 2 Number of CE patients according to the evolution of IgG levels observed between D030 and D365 for anti-B2t, anti-2B2t, and both antibodies (2B2t or B2t), and determination of the probability of being relapse-free
Antibody response | Evolution | NRCE, n (%) | RCE, n (%) | Probability of being relapse-free (%) |
|---|---|---|---|---|
Anti-B2t IgG | Decrease* | 25 (64) | 6 (30) | 81 |
Increase | 5 (13) | 8 (40) | ||
Stability | 9 (23) | 6 (30) | ||
Anti-2B2t IgG | Decrease | 21 (54) | 7 (35) | 75 |
Increase | 9 (23) | 10 (50) | ||
Stability | 9 (23) | 3 (15) | ||
Anti-(B2t or 2B2t) IgG | Decrease* | 32 (82) | 9 (45) | 78 |
Increase | 4 (10) | 7 (35) | ||
Stability | 3 (8) | 4 (20) |